Management of Moderately Hypertrophic Prostate with Rising PSA and Negative MRI

Current Clinical Picture

The National Comprehensive Cancer Network recommends that a moderately hypertrophic prostate gland (45-50cc) with no evidence of prostate tumor based on MRI criteria, multilobular high T2W foci consistent with age-related hypertrophic changes, negative staging parameters, and median lobe hypertrophy causing mild impingement on the bladder outlet, should be considered for continued monitoring 1

The National Comprehensive Cancer Network recommends regular PSA monitoring every 6-12 months as the first step in follow-up, with more frequent testing (every 3 months) for high-risk patients or those with rapidly rising values 2
The American College of Radiology recommends that PSA velocity (change over time) should be carefully monitored, as rapid rises (≥0.75 ng/mL per year) increase concern for cancer 3

The Journal of Clinical Oncology recommends that if PSA continues to rise despite negative MRI findings, next-generation imaging (NGI) should be considered, with PSMA-PET/CT as the preferred next imaging modality 4
The National Comprehensive Cancer Network recommends considering repeat prostate biopsy if PSA continues to rise despite negative imaging, with anteriorly directed biopsy and multiparametric MRI-guided targeted biopsies as options 5

The National Comprehensive Cancer Network recommends considering workup for benign disease if PSA elevation is modest and consistent with BPH, and addressing BPH symptoms may be warranted regardless of cancer concerns 5

The Journal of Clinical Oncology and the National Comprehensive Cancer Network recommend not dismissing rising PSA solely based on negative imaging, as persistent PSA elevation warrants continued vigilance 4, 2

The National Comprehensive Cancer Network recommends follow-up with PSA and DRE at 6-12 month intervals for patients with negative MRI and stable PSA, and considering more aggressive evaluation if PSA velocity increases significantly (>0.5 ng/mL per month) 5, 7
The Journal of Clinical Oncology recommends considering PSMA-PET/CT as the next step if PSA continues to rise, as it has superior detection capability for small volume disease compared to conventional imaging 4